NDAOTICSUSPENSION/DROPS
Approved
Feb 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
CIPRO HC (ciprofloxacin hydrochloride and hydrocortisone) by Novartis is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 1998.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CIPRO HC is a fixed-dose otic suspension combining ciprofloxacin (fluoroquinolone antibiotic) and hydrocortisone (corticosteroid) for topical ear use. It treats acute otitis externa and other otic infections by reducing inflammation and bacterial load. The corticosteroid component addresses the inflammatory pathway while the antibiotic provides antimicrobial coverage.
$0.04MPart D
LOE ApproachingDeclining
Product is approaching loss of exclusivity with modest Medicare spending; expect downsizing of brand team and shift toward generic or lifecycle management strategies.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CIPRO HC offers limited career advancement potential due to mature, LOE-approaching status and minimal linked job postings. Roles are primarily defensive (brand protection, generic transition management) rather than growth-oriented; best suited for professionals seeking stable, lower-intensity positions or gaining experience before transitioning to growth-stage products.
Brand Manager
Worked on CIPRO HC at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.